CD147 Promotes Tumor Lymphangiogenesis in Melanoma via PROX-1 - Archive ouverte HAL Access content directly
Journal Articles Cancers Year : 2021

CD147 Promotes Tumor Lymphangiogenesis in Melanoma via PROX-1

(1, 2) , (1) , (1) , (3) , (4) , (1, 2) , (2) , (1, 2) , (1, 2)
1
2
3
4

Abstract

Malignant melanoma is one of the most aggressive skin cancers and is characterized by early lymph node metastasis and the capacity to develop resistance to therapies. Hence, understanding the regulation of lymphangiogenesis through mechanisms contributing to lymphatic vessel formation represents a treatment strategy for metastatic cancer. We have previously shown that CD147, a transmembrane glycoprotein overexpressed in melanoma, regulates the angiogenic process in endothelial cells. In this study, we show a correlation between high CD147 expression levels and the number of lymphatic vessels expressing LYVE-1, Podoplanin, and VEGFR-3 in human melanoma lymph nodes. CD147 upregulates in vitro lymphangiogenesis and its related mediators through the PROX-1 transcription factor. In vivo studies in a melanoma model confirmed that CD147 is involved in metastasis through a similar mechanism as in vitro. This study, demonstrating the paracrine role of CD147 in the lymphangiogenesis process, suggests that CD147 could be a promising target for the inhibition of melanoma-associated lymphangiogenesis
Fichier principal
Vignette du fichier
cancers-13-04859-v2.pdf (9.02 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

pasteur-03366235 , version 1 (05-10-2021)

Licence

Attribution - CC BY 4.0

Identifiers

Cite

Coralie Reger de Moura, Alexandra Landras, Farah Khayati, Uwe Maskos, Kamel Maouche, et al.. CD147 Promotes Tumor Lymphangiogenesis in Melanoma via PROX-1. Cancers, 2021, This article belongs to the Special Issue New Emerging Connections in Tumor Angiogenesis, Lymphangiogenesis and Their Therapeutic Relevance, 13 (19), pp.4859. ⟨10.3390/cancers13194859⟩. ⟨pasteur-03366235⟩
29 View
37 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More